Compare MOH & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | NUVL |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.8B |
| IPO Year | 2002 | 2021 |
| Metric | MOH | NUVL |
|---|---|---|
| Price | $242.01 | $123.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | ★ $167.00 | $134.75 |
| AVG Volume (30 Days) | 875.7K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,426,000,000.00 | N/A |
| Revenue This Year | $2.40 | N/A |
| Revenue Next Year | $5.18 | $1,239.49 |
| P/E Ratio | $898.74 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $71.14 |
| 52 Week High | $243.50 | $123.97 |
| Indicator | MOH | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 76.58 | 67.22 |
| Support Level | $175.18 | $98.56 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 9.79 | 0.14 |
| MACD | 1.14 | -0.73 |
| Stochastic Oscillator | 96.76 | 95.45 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.